MorphoSys cuts R&D from Constellation deal to focus on clinical-stage cancer drugs

[cafead]

via MorphoSys is cutting the drug discovery and R&D work of Constellation Pharmaceuticals, a company it acquired lats year in a $1.7 billion deal. This consolidation of research operations will result in non-cash impairment charge on Constellation’s goodwill.

article source